

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

OVERSEAS REGULATORY ANNOUNCEMENT LEGEND BIOTECH ANNOUNCES TERMINATION OF COLLABORATIVE RESEARCH AND LICENSE AGREEMENT WITH NOILE

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) in relation to the termination of collaborative research and license agreement dated 27 April 2020 (the “**Agreement**”) between Legend Biotech USA, Inc. (“**Legend USA**”) and Noile-Immune Biotech, Inc. (“**Noile**”), effective on 28 January 2022. The Agreement was in relation to the development of chimeric antigen receptor (CAR-T) and/or T-cell receptor (TCR-T) therapies incorporating Noile’s PRIME (proliferation-inducing and migration-enhancing) technology secreting both IL-7 and CCL19.

Legend USA and Noile agreed to terminate the Agreement after the parties were not able to mutually agree upon an antigen target to be selected for further research. As of the date of this announcement, nil payment has been paid to Noile by the Company.

For details of the termination of the Agreement, please refer to the attached Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000115752322000136/0001157523-22-000136-index.htm>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 3 February 2022

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

Date of Report: February 2, 2022

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

**2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K shall be deemed to be incorporated by reference in the registration statements of Legend Biotech Corporation on Form F-3 (Nos. 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

Termination of Collaborative Research and License Agreement with Noile-Immune Biotech, Inc.

Legend Biotech USA, Inc. (“Legend Biotech”) and Noile-Immune Biotech, Inc. (“Noile”) have mutually agreed to terminate their Collaborative Research and License Agreement dated as of April 27, 2020 (as amended, the “Agreement”), effective on January 28, 2022. Legend Biotech and Noile agreed to terminate the Agreement after the parties were not able to mutually agree upon an antigen target to be selected for further research.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

(Registrant)

February 1, 2022

By: /s/ Ying Huang

Ying Huang, Ph.D.

Chief Executive Officer and Chief Financial Officer